Insider Selling: 10x Genomics (NASDAQ:TXG) CEO Sells $251,959.00 in Stock

10x Genomics (NASDAQ:TXG) CEO Serge Saxonov sold 13,261 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the completion of the transaction, the chief executive officer directly owned 1,021,556 shares in the company, valued at $19,409,564. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

10x Genomics Stock Down 5.3%

NASDAQ TXG traded down $1.06 during trading hours on Tuesday, reaching $19.07. 5,111,169 shares of the company were exchanged, compared to its average volume of 3,246,832. The stock has a market capitalization of $2.41 billion, a P/E ratio of -30.76 and a beta of 2.13. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $20.34. The business’s 50 day simple moving average is $13.55 and its 200-day simple moving average is $12.44.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The firm had revenue of $149.00 million for the quarter, compared to analysts’ expectations of $142.50 million. During the same period in the previous year, the company earned ($0.30) earnings per share. The company’s quarterly revenue was down 1.7% on a year-over-year basis. 10x Genomics has set its Q4 2025 guidance at EPS. As a group, sell-side analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on TXG shares. Morgan Stanley reduced their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday, August 12th. Canaccord Genuity Group upped their price target on 10x Genomics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Monday, November 17th. JPMorgan Chase & Co. boosted their price objective on 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Finally, Wall Street Zen downgraded shares of 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Hold” and a consensus target price of $14.88.

Institutional Trading of 10x Genomics

A number of hedge funds and other institutional investors have recently made changes to their positions in TXG. CIBC Bancorp USA Inc. purchased a new stake in 10x Genomics during the 3rd quarter worth about $134,000. Jacobs Levy Equity Management Inc. increased its position in shares of 10x Genomics by 22.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,947,989 shares of the company’s stock valued at $34,462,000 after buying an additional 550,250 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of 10x Genomics by 14.9% during the third quarter. CANADA LIFE ASSURANCE Co now owns 25,365 shares of the company’s stock valued at $287,000 after buying an additional 3,296 shares during the period. XTX Topco Ltd lifted its holdings in shares of 10x Genomics by 41.0% in the third quarter. XTX Topco Ltd now owns 81,070 shares of the company’s stock worth $948,000 after buying an additional 23,555 shares in the last quarter. Finally, Voleon Capital Management LP boosted its position in shares of 10x Genomics by 73.9% in the third quarter. Voleon Capital Management LP now owns 306,101 shares of the company’s stock valued at $3,578,000 after acquiring an additional 130,094 shares during the period. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.